Intuitive Surgical Inc. ($ISRG) Stock Forecast: Down 5.2% Today

What is Intuitive Surgical Inc.?

Intuitive Surgical Inc (ISRG) is a prominent player in the medical technology sector, known for its da Vinci Surgical System that revolutionizes minimally invasive surgery. Today, the stock experienced a significant bearish movement.

Why is Intuitive Surgical Inc. going down?

ISRG stock is down 5.2% on May 11, 2026 17:05

• ISRG stock plummeted by 5.77% due to a Class I FDA recall of certain staplers used with its da Vinci Surgical System, leading to serious injuries and one death. This news significantly impacted investor confidence in the company's technology and raised concerns about product safety.
• The additional selling pressure from major institutional investors like Koshinski Asset Management Inc. and Securian Asset Management Inc. further exacerbated the stock's decline, reflecting a lack of faith in ISRG's current valuation and potential future growth prospects.
• The broader sector-wide selling in medical technology stocks, including peers like Edwards Lifesciences and IDEXX Laboratories, suggests a macro or sentiment-driven market shift that contributed to ISRG's disproportionate fall. This market trend highlights the importance of monitoring industry dynamics and external factors that can influence stock performance.

ISRG Price Chart

ISRG Technical Analysis

ISRG News

Intuitive Surgical Inc Stock (ISRG) Moved Down by 5.77% on May 11: Key Drivers Unveiled

Intuitive Surgical Inc (ISRG) stock fell 5.77% on May 11, primarily due to a Class I FDA recall of certain staplers used with its da Vinci Surgical System, linked to serious injuries and one death. This decline was intensified by significant institutional selling by major investors like Koshinski Asset Management Inc. and Securian Asset Management Inc., alongside concerns about the stock's high valuation despite strong first-quarter earnings.

https://www.tradingkey.com/news/market-movers/261881135-market-movers-isrg-20260511

Intuitive Surgical Drops 6.3% Amid Sector-Wide Selling

Intuitive Surgical's stock dropped 6.3% on Monday to $421.86, caught in a broad wave of selling across the medical technology sector. Despite no company-specific negative news, the robotic surgery leader experienced a significant decline, alongside peers like Edwards Lifesciences and IDEXX Laboratories, suggesting a macro or sentiment-driven market shift. The disproportionate fall raises questions about its premium valuation or higher volatility in a declining market.

https://news.alphastreet.com/intuitive-surgical-drops-6-3-amid-sector-wide-selling/

GEHC Launches MIM ComboTherapy for GYN Cancer Radiation Planning

GE HealthCare (GEHC) has launched MIM ComboTherapy GYN HDR/EBRT, an advanced solution for radiation therapy planning in gynecologic cancers, including cervical and uterine cancers. This technology improves the accuracy of calculating total radiation dose distribution for complex combination therapies. The new solution aims to address a previous lack of innovation in women's health cancer care, offering clinicians clearer insights and supporting personalized, data-driven treatment strategies.

https://www.theglobeandmail.com/investing/markets/stocks/ISRG/pressreleases/1851991/gehc-launches-mim-combotherapy-for-gyn-cancer-radiation-planning/

Ies Holdings stock hits all-time high at 690.31 USD

IES Holdings Inc. (IESC) reached an all-time high of $690.31, reflecting a 171% increase over the past year. Despite this, InvestingPro analysis indicates the stock is currently overvalued. The company recently reported strong Q2 fiscal 2026 results driven by non-residential market expansion, leading Freedom Broker to downgrade its rating to "hold" while raising the price target to $700.

https://www.investing.com/news/company-news/ies-holdings-stock-hits-alltime-high-at-69031-usd-93CH-4677246

Medtronic PLC $MDT Stock Position Decreased by Swiss Life Asset Management Ltd

Swiss Life Asset Management Ltd reduced its stake in Medtronic PLC by 7.7% in the fourth quarter of the prior year, selling 66,041 shares but still holding 786,755 shares valued at approximately $75.6 million. Despite this reduction, analysts generally maintain a "Moderate Buy" rating on Medtronic with an average price target of $107.80. The company recently exceeded earnings expectations and paid a quarterly dividend of $0.71 per share, resulting in an annual yield of about 3.7%.

https://www.marketbeat.com/instant-alerts/filing-medtronic-plc-mdt-stock-position-decreased-by-swiss-life-asset-management-ltd-2026-05-11/

Trending Today

Intuitive Surgical Inc. Price History

22.03.2026 - ISRG Stock was up 6.9%

• ISRG stock saw a drop despite surpassing first-quarter predictions and increasing full-year guidance, potentially due to the guidance raise falling short of market expectations, indicating a likely slowdown ahead.
• Although showing a robust performance in Q1, marked by a 23% surge in sales and notable growth in da Vinci and Ion procedures, ISRG's careful guidance overshadowed its achievements, contributing to the bearish market trend.
• Investors seemed to react to the disparity between the impressive earnings report and the company's conservative forecast, leading to a stock decline despite positive operational outcomes.
• The market sentiment surrounding ISRG seems to reflect a balance between present performance and future growth possibilities, resulting in a varied response from investors.

22.03.2026 - ISRG Stock was up 5.7%

• Despite surpassing first-quarter forecasts and raising full-year guidance, Intuitive Surgical (ISRG) stock exhibited strong bullish momentum. The positive market response can be explained by several factors:
• The company posted robust first-quarter earnings, achieving a 23% sales increase to $2.8 billion and profits of $821.5 million, exceeding market expectations.
• Sales growth was primarily fueled by a 16% rise in da Vinci surgical system procedures and a 39% increase in the Ion endoluminal system.
• Intuitive Surgical's optimistic outlook, anticipating sustained double-digit growth for da Vinci procedures in 2026 and an expansion of installed systems globally, likely influenced the bullish market trend. The company's solid financial performance and favorable earnings report further enhanced investor confidence in its future outlook.

04.01.2026 - ISRG Stock was down 5.1%

• Machina Capital S.A.S. and other significant institutional investors have notably increased their holdings in ISRG, signaling confidence in the company's future.
• Despite positive Q3 performance and strategic growth positioning, ISRG witnessed a bearish movement, potentially attributed to profit-taking or shifts in market sentiment.
• The upcoming earnings release from Zimmer Biomet Holdings (ZBH) might have impacted market dynamics, leading to a more cautious approach towards medical equipment stocks like ISRG.
• Market sentiments surrounding healthcare and medical technology sectors likely influenced ISRG's bearish movement, despite its favorable long-term growth prospects.

10.11.2025 - ISRG Stock was down 2.8%

• An institutional investor increased its stake in ISRG by 1.2% in Q2, despite recent insider selling by executives, following the company's strong Q3 earnings.
• Another institutional investor, Daiwa Securities Group Inc., sold 6,055 shares of ISRG, reducing its holdings, while other institutional investors also adjusted their positions in the company.
• The market movement could be attributed to profit-taking by institutional investors after a period of significant growth, despite positive earnings and analyst consensus ratings.
• The bearish trend might also be influenced by overall market conditions and investor sentiment towards the healthcare sector, as highlighted by the positive performance of other surgical equipment companies in Q3.

06.00.2026 - ISRG Stock was up 3.7%

• Despite significant insider selling and reduced stakes by asset management firms, major institutional investors increasing their positions in ISRG have likely instilled confidence in the market.
• The utilization of AI in driving growth and innovation within the medical sector has positioned companies like Intuitive Surgical for strong performance, attracting investors and contributing to the bullish movement.
• While the stock may be trading at a premium valuation with a high P/E ratio, the perceived undervaluation and potential for future growth due to product innovation and AI integration have likely fueled investor optimism, leading to the bullish market movement.

06.00.2026 - ISRG Stock was up 5.0%

• Noteworthy insider selling by Greenleaf Trust and Hennion & Walsh Asset Management Inc. did not deter overall market optimism towards ISRG today.
• Discussions around the utilization of Artificial Intelligence (AI) in the medical sector, including within companies like ISRG, likely influenced investor sentiment positively, reflecting interest in the company's growth prospects.
• ISRG's strong earnings report, surpassing revenue and EPS projections, is seen as a key factor reinforcing investor trust in the company's future performance.
• Variations in institutional investors' behavior, with some increasing stakes and others decreasing positions in ISRG, suggest diverse views on the company's long-term outlook. Nevertheless, the prevailing market sentiment remained favorable, supporting the bullish trend in ISRG.

14.00.2026 - ISRG Stock was down 5.5%

• Despite strong Q4 revenue and procedure growth, ISRG's stock saw a 6% decline in pre-market trading.
• Concerns regarding a slowdown in Ion endoluminal system placements, despite an increase in da Vinci system placements, appear to have fueled the bearish movement.
• Investor sentiment may have been influenced by the company's anticipation of a potential deceleration in da Vinci procedures growth for 2026.
• Watching for the stock's current undervaluation in comparison to estimated fair value, as well as expected advancements in AI-enabled surgery, could be crucial for potential future market movements.

13.02.2026 - ISRG Stock was down 4.7%

• The bearish movement in ISRG stock today could be attributed to:
• Mixed short-term share performance contrasting with significant long-term gains, raising concerns about potential valuation risks.
• Underperforming the general market, including the S&P 500, Dow, and Nasdaq, despite analysts anticipating strong earnings and revenue growth.
• The stock trading at a premium valuation compared to industry peers, potentially leading to profit-taking by investors.
• The acquisition of distributors in Southern Europe could be a positive long-term strategic move for ISRG, enhancing its direct presence in key markets and further solidifying its position in the region.
• Analysts' suggestions of undervaluation and expectations of revenue growth over the next 12 months may indicate a potential rebound in the stock price following today's decline.

02.00.2026 - ISRG Stock was down 1.2%

• The downturn in ISRG stock today may be linked to investors seizing profits following a recent rise in the stock price.
• Despite notable developments like a robust Q3 performance and increased interest from institutional investors, market sentiment could be swayed by overall uncertainty and volatility in the healthcare domain.
• The forthcoming Q4 earnings call set for January 22 might influence the stock's trajectory, as investors await insights on future growth prospects.
• The market's perception of ISRG could also be influenced by broader economic conditions and industry trends impacting healthcare and technology sectors.

11.04.2026 - ISRG Stock was down 5.2%

• ISRG stock plummeted by 5.77% due to a Class I FDA recall of certain staplers used with its da Vinci Surgical System, leading to serious injuries and one death. This news significantly impacted investor confidence in the company's technology and raised concerns about product safety.
• The additional selling pressure from major institutional investors like Koshinski Asset Management Inc. and Securian Asset Management Inc. further exacerbated the stock's decline, reflecting a lack of faith in ISRG's current valuation and potential future growth prospects.
• The broader sector-wide selling in medical technology stocks, including peers like Edwards Lifesciences and IDEXX Laboratories, suggests a macro or sentiment-driven market shift that contributed to ISRG's disproportionate fall. This market trend highlights the importance of monitoring industry dynamics and external factors that can influence stock performance.

11.04.2026 - ISRG Stock was down 4.6%

• The bearish movement in Intuitive Surgical's stock today could be attributed to the mixed activity of institutional investors in the fourth quarter of 2025, with one firm reducing its stake while another increased its position.
• The ongoing market debate surrounding the valuation and future growth trajectory of the company may have contributed to the market reassessment and subsequent bearish movement.
• Despite the fluctuations in investor sentiment, Intuitive Surgical's market dominance with its innovative da Vinci system and robust recurring revenue model remains a key strength for the company.
• The overall uncertainty and conflicting actions of institutional investors regarding ISRG stock could have led to today's bearish market movement.